• news.cision.com/
  • WntResearch/
  • WntResearch´s Chief Financial Officer (CFO) Per-Ola Forsberg steps down from his position in the Company

WntResearch´s Chief Financial Officer (CFO) Per-Ola Forsberg steps down from his position in the Company

Report this content

"Per-Ola Forsberg has, during his time as CFO of WntResearch, for nearly five years, been essential in all aspects of the company's development. As he now resigns to move on to other pursuits, I would like to thank him for his commitment and the efforts he has made in WntResearch. I wish him the best of luck in all his future endeavours. Acting CEO Anders Rabbe will start the recruitment of a new CFO immediately," says Gudrun Anstrén, Chair of the Board.

For more information, please contact:

Anders Rabbe, Acting CEO, WntResearch AB
E-mail: anders.rabbe@wntresearch.com

Telephone: +46 707 646500

This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 15 October 2020.

About WntResearch

WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The Company focuses on WNT5A, a protein that suppresses the metastatic process in the body; the vision is for cancer patients to no longer have to endure metastasis. Today, one in every three people will develop cancer during their lifetimes, and 90 percent of all cancer-related deaths are caused by metastases. Even though cancer treatment has become more effective, there are no effective methods to prevent the formation of metastasis. The drug candidate Foxy-5 mimics WNT5A’ s ability to reduce the mobility and thus the spread of cancer cells. Foxy-5 has demonstrated a good safety profile with few adverse effects in two clinical phase I studies. An ongoing clinical phase II study is currently being conducted on patients with colon cancer with the Company's drug candidate Foxy-5. According to the Company's assessment, Foxy-5 is the only drug candidate of its kind, with a unique mode of action in an area where other drug or treatment options are lacking. WntResearch’s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com


Documents & Links